CRISPR Therapeutics AG had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $91.10 on 02/22/24, while the lowest price during the same period was $38.16 on 10/30/23.
52-week price history of CRSP Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. CRISPR Therapeutics AG’s current trading price is -47.37% away from its 52-week high, while its distance from the 52-week low is 25.66%. The stock’s price range during this period has fluctuated between $38.16 and $91.10. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 1.1 million for the day, which was evidently higher than the average daily volume of 1.09 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
CRISPR Therapeutics AG (CRSP) has experienced a quarterly decline of -17.21% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.08B and boasts a workforce of 407 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 51.60, with a change in price of -9.20. Similarly, CRISPR Therapeutics AG recorded 1,196,947 in trading volume during the last 100 days, posting a change of -16.10%.
CRSP Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
CRSP Stock Stochastic Average
The raw stochastic average for CRISPR Therapeutics AG over the last 50 days is presently at 52.86%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 72.52%. Further, the company’s Stochastic %K and %D values for the last 20 days were 59.71% and 68.99%, respectively.
CRSP Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Until today this year the stock’s price performance recorded a decrease of -23.40%. However, over the last six months, the performance has been stronger by -10.76%. The price of CRSP increased 4.42% over the last 30 days. And in the last five days, it has fallen by -0.70%.
